Genentech drug boosts leukemia patient survival
12/8/2008
Top Stories
- Gene therapy edges towards commercial reality The tale of two biotech companies suggests a tricky road ahead.
- Clean living could cut one third of common cancers Healthier living could prevent about one third of the most common cancers in rich countries
- Anti-nausea drug may combat opiate addiction in people addicted to morphine, oxycodone, and other opiate drugs
- Fertility Treatments Unlikely to Raise Ovarian Cancer Risk women taking fertility drugs in order to become pregnant have not had definitive evidence that such ...
- Depression risk increased among cancer patients People who have been diagnosed with cancer are at greater risk of being hospitalized with depression
- Cold's "family tree" may lead to cure: study Researchers who mapped the DNA of more than 100 different cold viruses
- Aspirin reduces risk of colon polyps recurring For people with a history of colorectal polyps or cancer, taking aspirin is an effective way to redu...
- A Smoker is More Likely To Quit Smoking If There Are Pets A large number of pet owners who smoke would consider trying to quit for the health of their beloved...
- Multivitamins may not thwart cancer, heart disease Millions of people take a multivitamin in the hopes of averting disease, but the supplements
- Gene therapy promising for rheumatoid arthritis Researchers have successfully used gene therapy to substantially reduce joint pain in two patients w...
12/8/2008
LOS ANGELES (Reuters) - A combination of Genentech Inc's cancer drug Rituxan and chemotherapy reduces by 41 percent the risk of death or cancer progression, compared with chemotherapy alone, for patients with a common form of leukemia, the company said on Saturday.
Results from the pivotal- or final-stage trial found that previously untreated patients given the combination therapy had a median progression-free survival of 42.8 months, compared with 32.3 months for those on chemotherapy alone, Genentech said.
The trial involved 817 patients with chronic lymphocytic leukemia, or CLL, the most common form of adult leukemia.
A separate trial of 552 CLL patients who had stopped responding to chemotherapy found the combination reduced the risk of death or cancer progression by 35 percent.
The studies, presented in San Francisco at a meeting of the American Society of Hematology, were sponsored by Genentech's majority owner Roche Holding AG, which markets Rituxan outside the United States under the brand name MabThera.
The drug, co-marketed in the United States by Genentech and Biogen Idec Inc, is approved to treat non-Hodgkin's lymphoma and rheumatoid arthritis. Rituxan, which had U.S. sales of $655 million in the third quarter, is an antibody designed to bind to a protein on the surface of B-cells where it recruits the body's natural defenses to attack and kill the marked cells.
GlaxoSmithKline PLC and Genmab are developing a similar antibody, called ofatumumab. Results from a smaller Phase 3 trial of that drug in CLL patients who have stopped responding to chemotherapy will be presented at the hematology conference on Monday.
For more information: www.yourcancertoday.com
© Reuters 2006. All rights reserved. Users may download and print extracts of content from this website for their own personal and non-commercial use only. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks or trademarks of the Reuters group of companies around the world.